Moreover, systemic delivery of CTX-coupled SNALPs-formulated anti-miR-21 oligonucleotides led to efficient release of the encapsulated nucleic acids into the brain tumors, which was associated with a significant and specific miR-21 silencing, resulting in increased mRNA and protein levels of its target, RhoB (Rho-related GTP-binding protein RhoB), while showing no signs of immunogenicity [159]. Here, RHOB is linked to brain neoplasm.